Nishinomiya, Japan

Yoshinori Aihara

USPTO Granted Patents = 4 


Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Location History:

  • Nishinomiya, JP (2020 - 2022)
  • Osaka, JP (2022)

Company Filing History:


Years Active: 2020-2024

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Yoshinori Aihara: Innovator in Neuropsychiatric Medicaments

Introduction

Yoshinori Aihara is a notable inventor based in Nishinomiya, Japan. He has made significant contributions to the field of neuropsychiatric treatments, holding a total of 4 patents. His work focuses on developing medicaments that target serotonin 5-HT receptors, which are crucial in treating various neuropsychiatric diseases.

Latest Patents

Among his latest patents, Aihara has developed compounds that show serotonin 5-HT receptor activity. One of his inventions is a medicament for treating neuropsychiatric diseases, comprising a compound of Formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient. Another significant patent involves substituted lactams that also demonstrate serotonin 5-HT receptor activity, aimed at providing therapeutic solutions for neuropsychiatric conditions.

Career Highlights

Throughout his career, Yoshinori Aihara has worked with prominent companies in the pharmaceutical industry. He has been associated with Sumitomo Pharma Co., Ltd. and Sumitomo Dainippon Pharma Co., Ltd., where he has contributed to the development of innovative treatments.

Collaborations

Aihara has collaborated with notable professionals in his field, including Jeremy Besnard and Andrew Simon Bell. These collaborations have likely enhanced the scope and impact of his research and inventions.

Conclusion

Yoshinori Aihara's contributions to the field of neuropsychiatric medicaments highlight his innovative spirit and dedication to improving mental health treatments. His patents reflect a commitment to advancing medical science and providing effective solutions for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…